MYCAPSSA

PeakPeptide

octreotide

NDAORALCAPSULE, DELAYED RELEASE
Approved
Jun 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20

Mechanism of Action

Somatostatin Receptor Agonists

Pharmacologic Class:

Somatostatin Analog

Clinical Trials (5)

NCT07262957Phase 4Recruiting

Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA)

Started Sep 2025
400 enrolled
Pancreas Head CancerPancreas AdenocarcinomaIPMN, Pancreatic+7 more
NCT05281328Phase 2/3Active Not Recruiting

A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD

Started Jun 2022
71 enrolled
Polycystic Liver Disease
NCT04941911Phase 2Unknown

A Feasibility Study of Octreotide Infusion During Liver Transplant.

Started May 2022
30 enrolled
Liver TransplantationRenal Failure
NCT05050942Phase 3Active Not Recruiting

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET

Started Oct 2021
332 enrolled
Gastro-enteropancreatic Neuroendocrine Tumor
NCT06254235Phase 1Completed

Bioequivalence Study of Two Octreotide Microsphere Formulations in Healthy Volunteers

Started Jun 2021
240 enrolled
Healthy Volunteers

Loss of Exclusivity

LOE Date
Dec 28, 2040
180 months away
Patent Expiry
Dec 28, 2040
Exclusivity Expiry
Jun 26, 2027

Patent Records (5)

Patent #ExpiryTypeUse Code
9566246
Sep 17, 2029
Product
11969471
Sep 17, 2029
Product
11986529
Sep 17, 2029
U-2857
8329198
Sep 17, 2029
Product
8535695
Sep 17, 2029
U-2857